ARTICLE 1 DEFINITIONSCollaboration and Option Agreement • April 15th, 2005 • Mymetics Corp • Biological products, (no disgnostic substances)
EXHIBIT 10.24 [/\#/\] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Collaboration and Option Agreement • October 28th, 2003 • Myogen Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.24 [/\#/\] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED....Collaboration and Option Agreement • October 9th, 2003 • Myogen Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.27 (WITH CERTAIN CONFIDENTIAL INFORMATION DELETED AND MARKED WITH BRACKETED ASTERIKS)Collaboration and Option Agreement • March 3rd, 2000 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
IL-1 BETACollaboration and Option Agreement • November 16th, 1998 • Cistron Biotechnology Inc • In vitro & in vivo diagnostic substances • York